Glycosaminoglycans, proteins, and stone formation: Adult themes and child's play

Pediatric Nephrology

Volumn 10, Issue 5, 1996, Pages 656-666

  Ryall, Rosemary L ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Glycosaminoglycans; Proteins; Stone formation

Indexed keywords

CALCIUM; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; INTER ALPHA TRYPSIN INHIBITOR; OSTEOPONTIN; OXALIC ACID; PROTEIN; PROTHROMBIN;

ADULT; CHILD; FEMALE; HUMAN; MALE; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; URINARY EXCRETION; UROLITHIASIS;

ADULT; ALPHA-GLOBULINS; CALCIUM OXALATE; CHILD; GLYCOPROTEINS; GLYCOSAMINOGLYCANS; HUMANS; KIDNEY CALCULI; MUCOPROTEINS; OSTEOPONTIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PROTEINS; PROTHROMBIN; SIALOGLYCOPROTEINS;

EID: 0029777336     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670050185     Document Type: Review

References (134)

1. Dorai CRT, Dewan PA, Boucaut HA, Erblich J (1994) Urolithiasis in Australian aboriginal children. Aust NZ J Surg 64:99-101
2. Shah AM, Kalmunkar S, Billimoria FR, Bapat SD, Deshmukh SS (1991) Spectrum of pediatric urolithiasis in western India. Indian J Pediatr 58:543-549
3. Androulakakis PA, Michael V, Polychronopoulou S, Aghioutantis C (1991) Paediatric urolithiasis in Greese. Br J Urol 67:206-209
4. Diamond DA, Rickwood AMK, Lee PE, Johnston JH (1994) Infection stones in children: a twenty seven year review. Pediatr Urol 43:525-527
5. Gearhart JP, Herzberg GZ, Jeffs RD (1991) Childhood urolithiasis: experiences and advances. Pediatrics 87:445-450
6. Basaklar AC, Kale N (1991) Experience with childhood urolithiasis. Br J Urol 67:203-205
7. Akinci N, Esen T, Kocak T, Ozsoy C, Tellaloglu S (1992) The role of inhibitor deficiency in urolithiasis. I. Rationale of urinary magnesium, citrate, pyrophosphate and glycosaminoglycan determinations. Eur Urol 19:240-243
8. Milliner DS, Murphy ME (1993) Urolithiasis in pediatric patients. Mayo Clin Proc 68:241-248
9. Lieberman E (1993) Importance of metabolic contributions to urolithiasis in pediatric patients (editorial). Mayo Clin Proc 68:313-315
10. Perrone HC, Santos DR dos, Santos MV, Pinheiro ME, Toporovski J, Ramos OL, Schor N (1992) Urolithiasis in childhood: metabolic evaluation. Pediatr Nephrol 6:54-56
11. De Santo NG, Di Iorio B, Capasso G, Paduano C, Stamler R, Langman CB, Stamler J (1992) Population based data on urinary excretion of calcium, magnesium, oxalate, phosphate and uric acid in children from Cimitile (southern Italy). Pediatr Nephrol 6:149-157
12. Stapleton FB (1994) Hematuria associated with hypercalciuria and hyperuricosuria: a practical approach. Pediatr Nephrol 8:756-761
13. Harangi F, Méhes K (1993) Family investigations in idiopathic hypercalciuria. Eur J Pediatr 152:64-68
14. Robertson WG, Hughes H (1993) Importance of mild hyperoxaluria in the pathogenesis of urolithiasis - new evidence from studies in the Arabian Peninsula. Scanning Microsc 7:391-402
15. Harmon EP, Neal DE, Thomas R (1994) Pediatric urolithiasis: review of research and current management. Pediatr Nephrol 8:508-512
16. Losty P, Surana R, O'Donnell B (1993) Limitations of extracorporeal shock wave lithotripsy for urinary tract calculi in young children. J Pediatr Surg 28:1037-1039
17. Jenkins AD (1991) Metabolic stone disease (editorial). J Urol 148:998-999
18. Baggio B, Gambaro G, Favaro S, Borsatti A, Pavanello L, Siviero B, Zaccjello G, Rizzoni GF (1983) Juvenile renal stone disease: a study of urinary promoting and inhibiting factors. J Urol 130:1133-1135
19. Michelacci YM, Glashan RQ, Schor N (1989) Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Urol Int 44:218-221
20. Lama G, Carbone MG, Marrone N, Russo P, Spagnolo G (1990) Promoters and inhibitors of calcium urolithiasis in children. Child Nephrol Urol 10:81-84
21. Harangi F, Györke Z, Melegh B (1996) Urinary glycosaminoglycan excretion in healthy and stone forming children. Pediatr Nephrol (in press)
22. Lowenstam HA, Weiner S (1989) On biomineralization. Oxford University Press, New York, p 324
23. Boyce W, Garvey FK (1956) The amount and nature of the organic matrix in urinary calculi: a review. J Urol 76:213-227
24. Boyce WH (1968) Organic matrix of human urinary concretions. Am J Med 45:673-683
25. Nishio S, Abe Y, Wakatsuki A, Iwata H, Ochi K, Takeuchi M, Matsumoto A (1985) Matrix glycosaminoglycan in urinary stones. J Urol 134:503-505
26. Khan SR, Shevock PN, Hackett RL (1988) Presence of lipids in urinary stones: results of preliminary studies. Calcif Tissue Int 42:91-96
27. Boyce WH, King J, Fielden M (1962) Total non-dialyzable solids (TNDS) in human urine. XIII. Immunological detection of a component peculiar to renal calculous matrix and to urine of calculous patients. J Clin Invest 41:1180-1189
28. Warpehoski MA, Buscemi PJ, Osborn DC, Finlayson Goldberg EP (1981) Distribution of organic matrix in calcium oxalate renal calculi. Calcif Tissue Int 33:211-222
29. Doyle IR, Ryall RL, Marshall VR (1991) Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon. Clin Chem 37:1589-1594
30. Morse R M, Resnick MI (1988) A new approach to the study of urinary macromolecules as a participant in calcium oxalate crystallization. J Urol 139:869-873
31. Iwata H, Kamei O, Abe Y, Nishio S, Wakatsuki A, Ochi K, Takeuchi M (1988) The organic matrix of urinary uric acid crystals. J Urol 139:607-610
32. Robertson WG, Peacock M, Nordin BEC (1968) Activity products in stone-forming and non-stone-forming urine. Clin Sci 34:579-594
33. Robertson WG, Peacock M (1972) Calcium oxalate crystalluria and inhibitors of crystallisation in recurrent renal stone-formers. Clin Sci 43:499-506
34. Hallson PC, Rose GA (1976) Crystalluria in normal subjects and stone formers with and without thiazide and cellulose phosphate treatment. Br J Urol 48:515-524
35. Ryall RL, Stapleton AMF (1995) Urinary macromolecules in calcium oxalate stone and crystal matrix: good, bad, or indifferent? In: Khan SR (ed) Calcium oxalate in biological systems. CRC Press, Boca Raton, Florida, pp 265-290
36. Khan SR, Hackett RL (1993) Role of organic matrix in urinary stone formation: an ultrastructural study of crystal matrix interface of calcium oxalate monohydrate stones. J Urol 150:239-245
37. Crawford JE, Crematy EP, Alexander AE (1968). The effect of natural and synthetic polyelectrolytes on the crystallization of calcium oxalate. Aust J Chem 21:1067-1072
38. Robertson WG, Peacock M, Nordin BEC (1973) Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 43:31-37
39. Pak CYC, Holt K, Zerwekh JE (1979) Attenuation by monosodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation. Invest Urol 17:138-140
40. Ryall RL, Harnett RM, Marshall VR (1981) The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 112:349-356
41. Fellström B, Danielson BG, Ljunghall S, Wikström B (1986) Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. Clin Chim Acta 158:229-235
42. Robertson WG, Scurr DS (1986) Modifiers of calcium crystallization found in urine. I. Studies with a continuous crystallizer using an artifical urine. J Urol 135:1322-1326
43. Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine J Urol 136:128-131
44. Kohri K, Garside J, Blacklock NJ (1989) The effect of glycosaminoglycans on the crystallization of calcium oxalate. Br J Urol 63:584-590
45. Norman RW, Scurr DS, Robertson WG, Peacock M (1984) Inhibition of calcium oxalate crystallisation by pentosan polysulfate in control subjects and stone formers. Br J Urol 56:594-598
46. Martin X, Werness PG, Bergert JH, Smith LH (1984) Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth. J Urol 132:786-788
47. Grases F, Gil JJ, Conte A (1989) Glycosaminoglycans inhibition of calcium oxalate crystalline growth and promotion of crystal aggregation. Colloids Surfaces 36:29-38
48. Osswald H, Weinheimer G, Schütt I-D, Ernst W (1989) Effective prevention of calcium-oxalate crystal formation in vitro and in vivo by pentosan polysulfate. In: Walker VR, Sutton RAL, Cameron ECB, Pak CYC, Robertson WG (eds) Urolithiasis. Plenum, New York, pp 141-144
49. Suzuki K, Miyazawa K, Tsugawa R (1989) Inhibitory effect of sodium pentosan polysulfate on the formation, growth and aggregation of calcium oxalate in vitro. Jpn J Urol 80:526-531
50. Cao LC, Boevé ER, Schröder FH, Robertson WG, Ketelaars GAM, De Bruijn (1992) The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration. J Urol 147:1643-1646
51. Bowyer RC, Brockis JG, McCulloch RK (1979) Glycosaminoglycans as inhibitors of calcium oxalate crystal growth and aggregation. Clin Chim Acta 95:23-28
52. Yamaguchi S, Yoshioka T, Utsonomiya M, Koide T, Osafune M, Okuyama A, Sonoda T (1993) Heparan sulfate in the stone matrix and its inhibitory effect on calcium oxalate crystallization. Urol Res 21:187-192
53. Sallis JD, Lumley ME (1979) On the possible role of glycosaminoglycans as natural inhibitors of calcium oxalate stones. Invest Urol 16:296-299
54. Goldberg JM, Cotlier E (1972) Specific isolation and analysis of mucopolysaccharides (glycosaminoglycans) from human urine. Clin Chim Acta 41:19-27
55. Wessler E (1971) The nature of the non-ultrafiltrable glycosaminoglycans of normal human urine. Biochem J 122:373-384
56. Fleisch H (1978) Inhibitors and promoters of stone formation. Kidney Int 13:361-371
57. Ryall RL, Harnett RM, Hibberd CM, Edyvane KA, Marshall VR (1991) Effects of chondroitin sulfate, human serum albumin and Tamm-Horsfall mucoprotein on calcium oxalate crystallization in undiluted human urine. Urol Res 19:181-188
58. Michelacci YM, Boim MA, Bergamaschi CT, Rovigatti RM, Schor N (1992) Possible role for chondroitin sulfate in urolithiasis: in vivo studies in an experimental model. Clin Chim Acta 208:1-8
59. Shum DKY, Gohel MDI (1993) Separate effects of urinary chondroitin sulfate and heparan sulfate upon the crystallization of urinary calcium oxalate: differences between stone formers and normal controls. Clin Sci 85:33-39
60. Suzuki K, Ryall RL (1996) The effect of heparan sulfate on the crystallization of calcium oxalate in undiluted, ultrafiltered human urine. Br J Urol (in press)
61. Miyazawa K, Suzuki K, Tsugawa R (1989) The quantitative study of inhibitory effect of pentosan polysulfate and chlorophyllin on the experimental calcium oxalate stone. Jpn J Urol 80:861-869
62. Roberts SD, Resnick MI (1986) Glycosaminoglycans content of stone matrix. J Urol 135:1078-1083
63. Suzuki K, Mayne K, Doyle IR, Ryall RL (1994) Urinary glycosaminoglycans are selectively included into calcium oxalate crystals precipitated from whole human urine. Scanning Microsc 8:523-530
64. Robertson WG, Peacock M, Heyburn PJ, Marshall DH, Clark PB (1978) Risk factors in calcium stone disease of the urinary tract. Br J Urol 50:449-454
65. Samuell CT (1981) A study of glycosaminoglycan excretion in normal and stone-forming subjects using a modified cetylpyridinium chloride technique. Clin Chim Acta 117:63-73
66. Caudarella R, Stefani F, Rizzoli E, Malavolta N, D'Antuono G (1983) Preliminary results of glycosaminoglycans excretion in normal and stone forming subjects: relationship with uric acid excretion. J Urol 129:665-667
67. Ryall RL, Marshall VR (1983) The value of the 24hr urine analysis in the assessment of stone formers attending a general hospital outpatient clinic. Br J Urol 55:1-5
68. Ryall RL, Darroch JN, Marshall VR (1984) The evaluation of risk factors in male stone formers attending a general hospital outpatient clinic. Br J Urol 56:116-121
69. Hesse A, Wuzel H, Vahlensieck W (1986) The excretion of glycosaminoglycans in the urine of calcium-oxalate-stone patients and healthy persons. Urol Int 41:81-87
70. Baggio B, Gambaro G, Cicerello E, Mastrosimone S, Marzaro G, Borsatti A, Pagano F (1987) Urinary excretion of glycosaminoglycans in urological disease. Clin Biochem 20:449-450
71. Hwang TIS, Preminger GM, Poindexter J, Pak CYC (1988) Urinary glycosaminoglycans in normal subjects and patients with stones. J Urol 139:995-997
72. Nikkilä MT (1989) Urinary glycosaminoglycan excretion in normal and stone-forming subjects: significant disturbance in recurrent stone formers. Urol Int 44:157-159
73. Nesse A, Garbossa G, Romero MC, Bogardo CE, Zanchetta JR (1992) Glycosaminoglycans in urolithiasis. Nephron 62:36-39
74. Keutel HJ, King JS, Boyce WH (1964) Further studies of uromucoid in normal and stone urine. Urol Int 17:324-341
75. Melick RA, Quelch KJ, Rhodes M (1980) The demonstration of sialic acid in kidney stone matrix. Clin Sci 59:401-404
76. Nakagawa Y, Ahmed M, Hall SL, Deganello S, Coe FL (1987) Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in γ-carboxyglutamic acid. J Clin Invest 79:1782-1787
77. Petersen TE, Thørgesen I, Petersen SE (1989) Identification of hemoglobin and two serine proteases in acid extracts of calcium containing kidney stones. J Urol 142:176-180
78. Fraij BM (1989) Separation and identification of urinary proteins and stone-matrix proteins by mini-slab sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Clin Chem 35:652-662
79. Shiraga H, Min W, VanDusen WJ, dayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Neilson EG, Hoyer JR (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily, Proc Natl Acad Sci USA 89:426-430
80. Umekawa T, Kohri K, Amasaki N, Yamate T, Yoshida K, Yamamoto K, Suzuki Y, Sinohara H, Kurita T (1993) Sequencing of a urinary stone protein identical to α1-antitrypsin. Biochem Biophys Res Commun 193:1049-1053
81. Binette JP, Binette MB (1993) A cationic protein from a uratecalcium oxalate stone: isolation and purification of a shared protein. Scanning Microsc 7:1107-1110
82. Binette JP, Binette MB (1994) Sequencing of proteins extracted from stones. Scanning Microsc 8:233-239
83. Dussol B, Geider S, Lilova A, Léonetti F, Dupuy P, Daudon M, Berland Y, Dagorn J-C, Verdier J-M (1995) Analysis of the soluble matrix of five morphologically different kidney stones. Urol Res 23:45-51
84. Stapleton AMF, Dawson CJ, Grover PK, Hohman A, Comac -chio R, Boswarva V, Tang Y, Ryall RL (1996) Further evidence linking urolithiasis and blood coagulation: urinary prothrombin fragment 1 is present in stone matrix. Kidney Int 49:880-888
85. Hess B (1991) The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microsc 5:689-696
86. Hess B (1992) Tamm-Horsfall glycoprotein - inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 20:83-86
87. Wallace AC, Nairn RC (1971) Tamm-Horsfall protein in kidneys of human embryos and foreign species. Pathology 3:303-310
88. Sikri KL, Foster CL, MacHugh N, Marshall RD (1981) Localization of Tamm-Horsfall glycoprotein in the human kidney using immuno-fluorescence and immuno-electron microscopical techniques. J Anat 132:597-605
89. Peach RJ, Day WA, Ellingson PJ, McGiven AR (1988) Ultrastructural localisation of Tamm-Horsfall protein in human kidney using immunogold electron microscopy. Histochem J 20:156-164
90. Hunt JS, McGiven AR, Grouvsky A, Lynn KL, Taylor MC (1994) Affinity-purified antibodies of defined specificity for use in a solid-phase microplate radioimmunoassay of human Tamm-Horsfall glycoprotein in urine. Biochem J 227:957-963
91. Robertson WG, Scurr DS, Bridge CM (1981) Factors influencing the crystallization of calcium oxalate in urine - a critique. J Cryst Growth 53:182-194
92. Kitamura T, Pak CYC (1982) Tamm and Horsfall glycoprotein does not promote spontaneous precipitation and crystal growth of calcium oxalate in vitro. J Urol 127:1024-1026
93. Hallson PC, Rose GA (1979) Uromucoids and urinary stone formation. Lancet 1:1000-1002
94. Grover PK, Ryall RL, Marshall VR (1990) Does Tamm-Horsfall mucoprotein inhibit or promote calcium oxalate crystallization in human urine? Clin Chim Acta 190:223-238
95. Rose GA, Sulaiman S (1982) Tamm-Horsfall mucoprotein promotes calcium phosphate crystal formation in urine: quantitative studies. J Urol 127:177-179
96. Grover PK, Ryall RL, Marshall VR (1994) Tamm-Horsfall mucoprotein reduces promotion of calcium oxalate crystal aggregation induced by urate in human urine in vitro. Clin Sci 87:137-144
97. Grant AMS, Baker LRI, Neuberger A (1973) Urinary Tamm-Horsfall glycoprotein in certain kidney disease and its content in renal and bladder calculi. Clin Sci 44:377-384
98. Bichler KH, Kirchner C, Ideler V (1976) Uromucoid excretion of normal individuals and stone formers. Br J Urol 47:733-738
99. Nakagawa Y, Kaiser ET, Coe FL (1978) Isolation and characterization of calcium oxalate crystal growth inhibitors from human urine. Biochem Biophys Res Commun 84:1038-1044
100. Nakagawa Y, Margolis HC, Yokoyama S, Kézdy FJ, Kaiser FT, Coe FL (1981) Purification and characterization of a calcium oxalate monohydrate crystals growth inhibitor from human kidney tissue culture medium. J Biol Chem 256:3936-3944
101. Nakagawa Y, Abram V, Kézdy FJ, Kaiser FT, Coe FL (1983) Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem 258:12594-12600
102. Nakagawa Y, Abram V, Coe FL (1984) Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine. Am J Physiol 247:F765-F772
103. Nakagawa Y, Abram V, Parks JH, Lau H S-H. Kawooya JK, Coe FL (1985) Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest 76:1455-1462
104. Nakagawa Y, Parks JH, Kézdy FJ, Coe FL (1985) Molecular abnormality of urinary glycoprotein crystal growth inhibitor in calcium nephrolithiasis. Trans Assoc Am Physicians 98:281-289
105. Coe FL, Margolis LH, Deutsch LH, Strauss AL (1980) Urinary macromolecular crystal growth inhibitors in calcium nephrolithiasis. Miner Electrolyte Metab 3:268-275
106. Netzer M, Nakagawa Y, Coe FL (1990) Characterization of a new antibody to nephrocalcin (NC), a major urinary inhibitor of calcium oxalate monohydrate (COM) crystal growth (abstract). Kidney Int 37:474
107. Nakagawa Y, Netzer M, Coe FL (1990) Immunohistochemical localization of nephrocalcin (NC) to proximal tubule and thick ascending limb of Henle's loop (TALH) of human and mouse kidney (abstract). Kidney Int 37:474
108. Nakagawa Y, Sirivongs D, Novy MB, Netzer M, Michaels E, Vogelzang NJ, Coe FL (1992) Nephrocalcin: biosynthesis by human renal carcinoma cells in vitro and in vivo. Cancer Res 52:1573-1579
109. Nakagawa Y, Netzer M, Michaels EK, Suzuki F, Ito H (1994) Nephrocalcin in patients with renal cell carcinoma. J Urol 152:29-34
110. Kaiser ET, Bock SC (1989) Protein inhibitors of crystal growth. J Urol 141:750-752
111. Hess B, Nakagawa Y, Coe FL (1989) Nephrocalcin isolated from human kidney stones is a defective calcium-oxalate-monohydrate crystal-aggregation inhibitor. In: Walker VR, Sutton RAL, Cameron EC, Pak CYC, Robertson WG (eds) Urolithiasis. Plenum, New York, pp 137-139
112. Worcester EM, Sebastian JL, Hiatt JG, Beshensky AM, Sadowski JA (1993) The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcif Tissue Int 53:242-248
113. Tang Y, Grover PK, Moritz RL, Simpson RJ, Ryall RL (1995) Is nephrocalcin related to the urinary derivative (bikunin) of interα-trypsin inhibitor? Br J Urol 75:425-430
114. Reinholt FP, Hultenby K, Oldberg A, Heingard D (1990) Osteopontin - a possible anchor of osteoblasts to bone. Proc Natl Acad Sci USA 87:4473-4475
115. Addadi L, Weiner S (1985) Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 82:4110-4114
116. Prince CW, Oosawa T, Butler WT, Tomann M, Bhown AS, Bhown M, Schrohenloher RE (1987) Isolation, characterization and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 262:2900-2907
117. Kiefer MC, Bauer DM, Barr PJ (1989) The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res 17:3306
118. Worcester EM, Blumenthal SS, Beshensky A (1992) The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7:1029-1036
119. Kohri K, Suzuki Y, Yoshida K, Yamamoto K, Amasaki N, Yamate T, Umekawa T, Iguchi M, Sinohara H, Kurita T (1992) Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin. Biochem Biophys Res Commun 184:859-864
120. Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T, Suzuki Y, Sinohara H, Kurita T (1993) Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 268:15180-15184
121. Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Cell Biol 3:1169-1180
122. Hoyer JR (1995) Uropontin in urinary calcium stone formation. Miner Electrolyte Metab 20:385-392
123. Stapleton AMF, Simpson RJ, Ryall RL (1993) Crystal matrix protein is related to human prothrombin. Biochem Biophys Res Commun 195:1199-1203
124. Stapleton AMF, Ryall RL (1995) Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br J Urol 75:712-719
125. Degen SJF (1992) The prothrombin gene and its liver-specific expression. Semin Thromb Hemost 18:230-242
126. Stapleton AMF, Seymour AE, Brennan JS, Doyle IR, Marshall VR, Ryall RL (1993) The immunohistochemical distribution and quantification of crystal matrix protein. Kidney Int 44:817-824
127. Ryall RL, Grover PK, Stapleton AMF, Barrell DK, Tang Y, Moritz RL, Simpson RJ (1995) The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci 89:533-541
128. Sørenson S, Hansen K, Bak S, Justesen SJ (1990) An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res 18:373-379
129. Salier J-P ( 1990) Inter-α-trypsin inhibitor: emergence of a family within the Kunitz-type protease inhibitor superfamily. Trends Biochem Sci 15:435-439
130. Atmani F, Lacour B, Drücke T, Daudon M (1993) Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization. Urol Res 21:61-66
131. Atmani F, Lacour B, Strecker G. Parvy P, Drücke T, Daudon M (1993) Molecular characteristics of uronic-acid-rich protein, a strong inhibitor of calcium oxalate crystallization in vitro. Biochem Biophys Res Commun 191:1158-1165
132. Atmani F, Lacour B, Jungers P, Drücke T, Daudon M (1994) Reduced inhibitory activity of uronic-acid-rich protein (UAP) in the urine of stone formers. Urol Res 22:257-260
133. Atmani F, Khan SR (1995) Characterization of uronic-acid-rich inhibitor of calcium oxalate crystallization isolated from rat urine. Urol Res 23:95-101
134. Hochstrasser K, Reisinger P, Albrecht G, Wachter E, Schönberger ÖL (1984) Isolation of acid-resistant urinary trypsin inhibitors by high performance liquid chromatography and their characterization by N-terminal amino-acid sequence determination. Hoppe-Seyler's Z physiol Chem 365:1123-1130